TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04614337
Drug: LUM-201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally once daily
Study: NCT04614337
Drug: rhGH Norditropin® pen (34 µg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) once daily.
Study: NCT01064726
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg oral
Study: NCT01064726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02442960
Drug: Herbal treatment (SA100)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment has been used extensively in traditional medicine practices for hundreds of years.
Study: NCT01081756
Drug: r-hCG
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
Study: NCT00694057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules BID
Study: NCT01044719
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin 7mg/kg/day OD IV
Study: NCT03463187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT00301860
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01606241
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04573504
Drug: Augmentin/Flagyl or Augmentin/Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
Study: NCT04573504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01202084
Drug: Foraseq®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03756961
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
Study: NCT02140255
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
Study: NCT02924727
Drug: LCZ696 (sacubitril/valsartan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Study: NCT03664544
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg MCI-186 will be administered intravenously over 60 minutes.
Study: NCT04470037
Drug: DAAOI-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAOI-P 250-1500mg
Study: NCT04470037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch pill
Study: NCT00835367
Drug: Lotrel® 10 mg-20 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10-20 mg
Study: NCT00835172
Drug: AMARYL® 4 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 4 mg, single-dose non-fasting
Study: NCT03424733
Drug: Tylenol Pill
Normalized name: Tylenol Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Study: NCT03462121
Drug: RPh201
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPh201 is a well-defined extract from a botanical source
Study: NCT01524744
Drug: Adcortyl
Normalized name: Adcortyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone acetonide 0.1% in orabase
Study: NCT01556334
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 1g po
Study: NCT01556334
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin IV then PO
Study: NCT00977444
Drug: kondrium
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular injections once month
Study: NCT00977444
Drug: kondrium f
Normalized name: Stomodine F
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraarticular injections once month
Study: NCT04218981
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
Study: NCT04218981
Drug: Mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choose lithium or valproate for bipolar disorder group
Study: NCT01137084
Drug: a steroid-free immunosuppression protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
Study: NCT02140255
Drug: VRC01
Normalized name: VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg administered subcutaneously.
Study: NCT02140255
Drug: VRC07-523LS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg administered subcutaneously.
Study: NCT00864357
Drug: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
Study: NCT00864357
Drug: COMBONOX® tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
Study: NCT00830531
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Study: NCT00685295
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl rapid dissolving tablet 100mcg
Study: NCT03440411
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg every other day as oral administration (PO) on days 1-28
Study: NCT03446690
Drug: MI Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
Study: NCT01882816
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
Study: NCT01900184
Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01900184
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains magnesium stearate, silica dental type, anhydrous lactose
Study: NCT00688740
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT00688740
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous
Study: NCT00095576
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
Study: NCT01096004
Drug: AZD4017
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral suspension, 1200mg, once daily, for 10 days
Study: NCT01096004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03859219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: solution for injection~* Route of administration: subcutaneous infusion
Study: NCT06192420
Drug: Traumeel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study: NCT06192420
Drug: Diclofenac sodium gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study: NCT06192420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of gel three times daily for 7days (+1 day visit window)
Study: NCT00392574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00924092
Drug: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00358878
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT02407119
Drug: 7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
Study: NCT02407119
Drug: Placebo, Omeprazole or Rabeprazole, Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
Study: NCT02323048
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar pill)
Study: NCT01027676
Drug: Study treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250mg/QD plus vorinostat D1\~7 \& D15-21 / QD q 4weeks
Study: NCT01217892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01098890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered every 12 hours for a maximum of 5 doses.
Study: NCT04345614
Drug: Auxora
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auxora will be given at 2.0 mg/kg (1.25 mL/kg) on Day 1 and then 1.6 mg/kg (1.0 mL/kg) on Days 2 and 3. All doses of Auxora will be administered intravenously (IV) over 4 hours.
Study: NCT04345614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given at 1.25 mL/kg on Day 1 and then 1.0 mL/kg on Days 2 and 3. All doses of placebo will be administered intravenously over 4 hours.
Study: NCT00947531
Drug: 0.9% Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00415636
Drug: IC83/LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2.
Study: NCT00415636
Drug: IC83/LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Study: NCT00415636
Drug: IC83/LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Study: NCT00415636
Drug: IC83/LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Study: NCT00415636
Drug: IC83/LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: 195 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
Study: NCT00331721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT03914690
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
Study: NCT01737905
Drug: Epinephrine HFA-MDI (E004)
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose 125 mcg/inhalation, 2 inhalations
Study: NCT01737905
Drug: Placebo-HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 0 mcg/inhalation, 2 inhalations
Study: NCT02769104
Drug: AC*4-T*4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks\*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks\*4cycles
Study: NCT04438824
Drug: INCMGA00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA00012: 500 mg IV (flat dose) q28 days (+/- 7 days in each cycle)
Study: NCT03879382
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT02081703
Drug: AYX1 Injection 660 mg / 6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1
Study: NCT02081703
Drug: AYX1 Injection 1100 mg / 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL solution for intrathecal injection with 1100 mg of AYX1
Study: NCT02081703
Drug: Placebo Injection 6 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT02081703
Drug: Placebo Injection 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study: NCT04344795
Drug: TPST-1495 twice daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TPST-1495 administered orally twice daily
Study: NCT04344795
Drug: TPST-1495 once daily or on intermittent schedule
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TPST-1495 administered orally once daily or on intermittent schedule
Study: NCT04099901
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
Study: NCT02239003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02630641
Drug: Gonadotropin-releasing Hormone (GnRH) agonist therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
Study: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
Study: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Study: NCT00648414
Drug: Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: tourniquet applied just above patch application site, while samples collected
Study: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
Study: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tourniquet applied just below patch application site and above blood draw site, while samples collected
Study: NCT00648414
Drug: Duragesic 25 mcg/h + Clinical Procedure 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: tourniquet applied just above patch application site, while samples collected
Study: NCT03038620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Study: NCT01233947
Drug: AFP464
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
Study: NCT01233947
Drug: AFP464 + Faslodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
Study: NCT02480049
Drug: Asmakast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 10 mg of montelukast
Study: NCT03430999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01283984
Drug: AZD2115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT01283984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT02665377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02766855
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
Study: NCT01506726
Drug: Salsalate
Normalized name: Salsalate
DrugBank: Salsalate (DB01399)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
Study: NCT01506726
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
Study: NCT01753752
Drug: Chitosan- N- Acetylcysteine eye drops
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00224549
Drug: irbesartan, amlodipine and hydrochlorothiazide
Normalized name: irbesartan, amlodipine and hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: irbesartan, amlodipine and hydrochlorothiazide
Study: NCT01753752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04147286
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo
Study: NCT01969578
Drug: Cisplatin + Doxorubicin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03792269
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03336606
Drug: MEDI0562
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection of tumor
Study: NCT04293432
Drug: Drugs, Generic
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs having ≥10 TdP cases reported in the FAERS database
Study: NCT03589833
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
Study: NCT03984578
Drug: CAPEOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
Study: NCT03984578
Drug: Capecitabine/ 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
Study: NCT01841476
Drug: POL6326
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02399228
Drug: 0.25% EISO mouth rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
Study: NCT00934180
Drug: Zofran®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 8 mg ODT
Study: NCT01050114
Drug: onaBoNT-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder.
Study: NCT00420706
Drug: SCA-136
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03296982
Drug: Saline sham
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01990690
Drug: anti oxidant omega 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
Study: NCT01357681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02185183
Drug: Alequel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alequel
Study: NCT03037749
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage measured to mimic the smell and taste of the alcohol beverage.